ASND
Price
$175.57
Change
+$12.73 (+7.82%)
Updated
Jun 2, 04:59 PM (EDT)
Capitalization
10.63B
98 days until earnings call
ORMP
Price
$2.39
Change
+$0.05 (+2.14%)
Updated
Jun 2, 04:58 PM (EDT)
Capitalization
97.22M
72 days until earnings call
Interact to see
Advertisement

ASND vs ORMP

Header iconASND vs ORMP Comparison
Open Charts ASND vs ORMPBanner chart's image
Ascendis Pharma A/S
Price$175.57
Change+$12.73 (+7.82%)
Volume$4.47K
Capitalization10.63B
Oramed Pharmaceuticals
Price$2.39
Change+$0.05 (+2.14%)
Volume$100
Capitalization97.22M
ASND vs ORMP Comparison Chart
Loading...
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASND vs. ORMP commentary
Jun 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASND is a Hold and ORMP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 03, 2025
Stock price -- (ASND: $175.69 vs. ORMP: $2.38)
Brand notoriety: ASND and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASND: 176% vs. ORMP: 172%
Market capitalization -- ASND: $10.63B vs. ORMP: $97.22M
ASND [@Biotechnology] is valued at $10.63B. ORMP’s [@Biotechnology] market capitalization is $97.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASND’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • ASND’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than ASND.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASND’s TA Score shows that 7 TA indicator(s) are bullish while ORMP’s TA Score has 6 bullish TA indicator(s).

  • ASND’s TA Score: 7 bullish, 3 bearish.
  • ORMP’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ASND is a better buy in the short-term than ORMP.

Price Growth

ASND (@Biotechnology) experienced а +8.45% price change this week, while ORMP (@Biotechnology) price change was +12.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.09%. For the same industry, the average monthly price growth was +1.10%, and the average quarterly price growth was -0.30%.

Reported Earning Dates

ASND is expected to report earnings on Sep 09, 2025.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+4.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASND($10.6B) has a higher market cap than ORMP($97.2M). ASND YTD gains are higher at: 27.617 vs. ORMP (-3.306). ORMP has higher annual earnings (EBITDA): 9.44M vs. ASND (-305.15M). ASND has more cash in the bank: 518M vs. ORMP (142M). ORMP has less debt than ASND: ORMP (429K) vs ASND (847M). ASND has higher revenues than ORMP: ASND (369M) vs ORMP (0).
ASNDORMPASND / ORMP
Capitalization10.6B97.2M10,905%
EBITDA-305.15M9.44M-3,233%
Gain YTD27.617-3.306-835%
P/E RatioN/A20.91-
Revenue369M0-
Total Cash518M142M365%
Total Debt847M429K197,436%
FUNDAMENTALS RATINGS
ASND vs ORMP: Fundamental Ratings
ASND
ORMP
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
9979
PRICE GROWTH RATING
1..100
4951
P/E GROWTH RATING
1..100
10050
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (59) in the Pharmaceuticals Other industry is in the same range as ASND (90) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ASND’s over the last 12 months.

ASND's Profit vs Risk Rating (77) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that ASND’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (79) in the Pharmaceuticals Other industry is in the same range as ASND (99) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ASND’s over the last 12 months.

ASND's Price Growth Rating (49) in the Biotechnology industry is in the same range as ORMP (51) in the Pharmaceuticals Other industry. This means that ASND’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for ASND (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than ASND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASNDORMP
RSI
ODDS (%)
Bearish Trend 4 days ago
71%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
68%
Momentum
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 5 days ago
71%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 25 days ago
77%
Bearish Trend 15 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
79%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FCG22.480.46
+2.09%
First Trust Natural Gas ETF
LDEM51.190.47
+0.93%
iShares® ESG MSCI EM Leaders ETF
FBT161.880.60
+0.37%
First Trust NYSE Arca Biotech ETF
SSPY79.760.03
+0.04%
Stratified LargeCap Index ETF
AVUV87.98-0.15
-0.17%
Avantis US Small Cap Value ETF